Elizabeth Andrews, PhD

Vice President, Pharmacoepidemiology and Risk Management

PhD, Epidemiology
MPH, Health Policy and Administration, North Carolina School of Public Health
University of North Carolina, Chapel Hill, NC

BA
University of North Carolina, Chapel Hill, NC

Elizabeth Andrews, PhD, MPH, FISPE, is the Vice President of Pharmacoepidemiology and Risk Management at RTI-HS. She provides consultation for pharmaceutical companies and the US Food and Drug Administration (FDA) on therapeutic risk management and pharmacoepidemiology, and she directs research programs that evaluate drug safety and compliance with prescribing and treatment guidelines. She oversees the conduct of large, prospective patient registries, surveys, and studies using large existing databases. Dr. Andrews currently serves as principal investigator on several large risk management studies and serves on various study advisory boards and data safety monitoring boards. Her experience has spanned most therapeutic areas, although she has worked extensively in the areas of HIV and sexually transmitted diseases; birth defects and neonatal health; asthma and chronic obstructive pulmonary disease and irritable bowel syndrome. Dr. Andrews is involved in the design of observational research programs within RTI-HS to assure that the methods chosen provide a robust and cost-effective approach to address the study questions. She also assures appropriate linkages are forged with academic and governmental partners.

Previously, Dr. Andrews was Vice President, Worldwide Epidemiology, at GlaxoSmithKline and conducted epidemiologic research in a variety of therapeutic areas, including rheumatoid arthritis, genital herpes, HIV, asthma, migraine, and irritable bowel syndrome. She initiated the first pharmaceutical pregnancy registry, the Acyclovir Pregnancy Registry, and multiple registries for other medications. She began her career in the pharmaceutical industry at Burroughs Wellcome in 1982 and subsequently built a strong international epidemiology program at Glaxo Wellcome. Prior to joining Burroughs Wellcome, she managed the Statewide Regionalized Perinatal Care Program and directed the non-Medicaid health care reimbursement programs for the State Health Department of North Carolina.

She is a Fellow and Past President of the International Society for Pharmacoepidemiology, and a co-editor of Pharmacovigilance. She is an Adjunct Associate Professor of the University of North Carolina School of Public Health and School of Pharmacy, and a member of the Steering Committee for the Innovation in Medical Evidence Development and Surveillance (IMEDS) Program of the Reagan Udall Foundation for the FDA.